omega-3 Fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study.

  title={omega-3 Fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study.},
  author={Mary C. Zanarini and Frances R. Frankenburg},
  journal={The American journal of psychiatry},
  volume={160 1},
OBJECTIVE The purpose of this study was to compare the efficacy of ethyl-eicosapentaenoic acid (E-EPA) and placebo in the treatment of female subjects with borderline personality disorder. METHOD The authors conducted an 8-week, placebo-controlled, double-blind study of E-EPA in 30 female subjects meeting Revised Diagnostic Interview for Borderlines and DSM-IV criteria for borderline personality disorder. RESULTS Twenty subjects were randomly assigned to 1 g of E-EPA; 10 subjects were given… 

Tables from this paper

Efficacy of omega-3 fatty acids in the treatment of borderline personality disorder: A study of the association with valproic acid

A 12-week controlled trial aimed to assess the efficacy of the association of EPA and DHA with valproic acid, compared to single valproIC acid, in 43 consecutive BPD outpatients.

Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study

Lamotrigine appears to be a safe and effective agent in the treatment of anger in women with criteria-defined BPD as defined by SCID criteria, and it did not produce any clinically significant effect on body weight.

No Impact of Omega-3 Fatty Acid Supplementation on Symptoms or Hostility Among Patients With Schizophrenia

The implication is that Omega-3 fatty acids do not reduce psychopathology and hostility in acute patients with schizophrenia.

Omega-3 Fatty Acid Supplementation in Adolescents with Borderline Personality Disorder and Ultra-High Risk Criteria for Psychosis: A Post Hoc Subgroup Analysis of a Double—Blind, Randomized Controlled Trial

Whether long-chain omega-3 (n-3) polyunsaturated fatty acids (PUFAs) improve functioning and psychiatric symptoms in young people with borderline personality disorder (BPD) who also meet ultra-high risk criteria for psychosis is investigated.

Omega‐3 Fatty Acids in Depression: A Review of Three Studies

Omega‐3 fatty acids were shown to be more effective than placebo for depression in both adults and children in small controlled studies and in an open study of bipolar depression.

Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study.

Topiramate appears to be a safe and effective agent in the treatment of anger in women with borderline personality disorder as defined by SCID criteria, and significant weight loss can be expected.

Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid?

While it is not currently possible to recommend omega-3 PUFA as either a mono- or adjunctive-therapy in any mental illness, the available evidence is strong enough to justify continued study, especially with regard to attentional, anxiety and mood disorders.

Effects of Omega-3 in the treatment of violent schizophrenia patients

Olanzapine Versus Haloperidol in the Management of Borderline Personality Disorder: A Randomized Double-Blind Trial

There seems to be no significant difference between olanzapine and haloperidol regarding the management of mental and behavioral symptoms of patients with BPD.



Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.

Omega3 fatty acids were well tolerated and improved the short-term course of illness in this preliminary study of patients with bipolar disorder.

Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder.

It is not possible to distinguish whether E-EPA augments antidepressant action in the manner of lithium or has independent antidepressant properties of its own.

A New Depression Scale Designed to be Sensitive to Change

The construction of a depression rating scale designed to be particularly sensitive to treatment effects is described, and its capacity to differentiate between responders and non-responders to antidepressant treatment was better than the HRS, indicating greater sensitivity to change.

The Revised Diagnostic Interview for Borderlines: Discriminating BPD from other Axis II Disorders

The Diagnostic Interview for Borderlines (DIB) was revised to sharpen its ability to discriminate between clinically diagnosed borderline patients and patients with other types of Axis II clinical

The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description.

The history, rationale, and development of the Structured Clinical Interview for DSM-III-R (SCID) is described. The SCID is a semistructured interview for making the major Axis I DSM-III-R diagnoses.

Fatty acids : physiological and behavioral functions

Part I. Basic Mechanisms Evolutionary Aspects of Diet: Essential Fatty Acids Artemis P. Simopoulos Modulation of Receptor Signaling by Phospholipid Acyl Chain Composition Drake C. Mitchell and Burton